ArticleHaematologica2025
Comprehensive characterization of platelet function in dogs with hyperadrenocorticism.
Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperadrenocorticism (HAC) leads to a hypercoagulable state and contributes to the risk of thromboembolic disease. Hypercoagulation in HAC occurs in both humans and dogs. Platelets play a major role in thrombosis and hemostasis, but no study has investigated platelet function in dogs with HAC. Thus, we aimed to characterize the platelet function and its molecular mechanism in dogs with HAC by using platelets isolated from normal dogs and dogs with HAC. This prospective cross-sectional study included seven dogs with HAC and 15 normal dogs. Various platelet functional responses including platelet aggregation and dense granule secretion were evaluated. 2-MeSADP- and low concentration of thrombin-induced platelet aggregation and secretion were significantly inhibited in dogs with HAC compared to normal dogs. Furthermore, the pre-incubation of platelets with prednisolone inhibited 2-MeSADP- and thrombin-induced platelet aggregation and secretion only in normal dog platelets, whereas no additional inhibitory effect was shown in dogs with HAC confirming a role of excessive cortisol in platelet function. In addition, 2-MeSADP- and thrombin-induced platelet aggregation and post-adrenocorticotropic hormone (ACTH) cortisol levels showed a negative correlation. Moreover, 2-MeSADP- and thrombin-induced thromboxane A2 (TxA2) generation was significantly inhibited in dogs with HAC compared to normal dogs, confirming the role of cortisol in TxA2 generation. Finally, thrombin-induced ERK and AKT phosphorylation were significantly inhibited in dogs with HAC. In conclusion, excessive cortisol in dogs with HAC affects platelet function by suppressing TxA2 generation through the regulation of ERK and AKT phosphorylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.